Specifically, germline BRCA1/2 mutations associate with increased risk and with more aggressive prostate cancer (Gleason ≥ 8), higher risk of nodal involvement, and distant metastasis at diagnosis [41]. The gene discussed is BRCA1; the disease is prostate carcinoma.